Kristel De Boeck - Infectious Diseases

Author Information

Kris De Boeck is a distinguished expert in the field of Pediatric Pulmonology and Infectious Diseases. She is affiliated with the University Hospital of Leuven and the University of Leuven in Belgium. Her work largely focuses on cystic fibrosis, emphasizing both clinical and research dimensions to improve patient outcomes.

Research Contributions

Kris De Boeck has made significant contributions to the understanding and treatment of cystic fibrosis. Her research spans various aspects of the disease, including long-term safety and efficacy of treatments like tezacaftor-ivacaftor, characterization of CFTR function, and innovative diagnostic tools such as rectal organoid morphology analysis. She has also explored the impacts of dietary interventions and small molecule screening in managing the disease, reflecting a comprehensive approach to cystic fibrosis therapeutics and patient management.

Aliases

Kris De Boeck is also known by several variations of her name, including K De Boeck, K. De Boeck, and Kristel De Boeck.

Publication and Citation Metrics

Metric	Value
Publication Count	173
Citation Count	6569
H-index	44

Publications:

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

DOI: 10.1016/S2213-2600(20)30510-5

Year: 2021

P023 Characterisation of CFTR function in a patient with the F508del/ CFTRdup1–3 genotype

DOI: 10.1016/S1569-1993(21)01050-X

Year: 2021

The journal of cystic fibrosis' 20th anniversary.

DOI: 10.1016/j.jcf.2021.11.016

Year: 2021

Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis

DOI: 10.1136/thoraxjnl-2020-216368

Year: 2021

WS09.2 Elexacaftor combinations (partially) restore CFTR function to previously drug-refractory mutations G85E and N1303K

DOI: 10.1016/S1569-1993(21)00964-4

Year: 2021

A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe

DOI: 10.3389/fphar.2021.746710

Year: 2021

Mucus Release and Airway Constriction by TMEM16A May Worsen Pathology in Inflammatory Lung Disease

DOI: 10.3390/ijms22157852

Year: 2021

Change in Nutrient and Dietary Intake in European Children with Cystic Fibrosis after a 6-Month Intervention with a Self-Management mHealth Tool

DOI: 10.3390/nu13061801

Year: 2021

P031 The last 10%: small molecule screening for correctors of rare CFTRprocessing mutations

DOI: 10.1016/s1569-1993(21)01058-4

Year: 2021

Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.

DOI: 10.1016/j.jcf.2020.05.012

Year: 2020

How is Plasmodium falciparum diagnosed?

How Can Technology Help?

What Role Does Research Play in CDC Activities?

How is Malaria Diagnosed and Treated?

What Do the Results Mean?

What are the Global Implications?

What Diseases Does DTaP Protect Against?

How do Bacteria Cause Diseases?

What are the Risks of Untreated Infections During Pregnancy?

What are the Challenges in Controlling Dengue Hemorrhagic Fever?

Partnered Content Networks

Relevant Topics